If the findings of a tiny Philadelphia company hold up, doctors would for the first time have a reliable way to diagnose Alzheimers in patients with memory problems.

New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer’s disease (AD). The study, published by Cell Press in the June 10 issue of the journal Neuron, advances our understanding of the link between vascular pathology and AD and proposes a new therapeutic strategy aimed at slowing cognitive decline.

A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors (ChEI), a type of medication often prescribed for Alzheimer’s disease (AD), improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive …

( BMJ-British Medical Journal ) A special dementia care plan, involving regular assessments of patients with Alzheimer’s disease in specialist memory clinics, does not slow functional decline compared with usual care, finds a study published on bmj.com today.

WATERTOWN, Mass., May 11 /PRNewswire/ — EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease.

Buoyed by early results of stem cell-based trials on patients with Lou Gehrig’s disease, Eva Feldman, M.D., co-director of the A.

WEDNESDAY, April 14 (HealthDay News) — Involuntary crying or laughing can be a common symptom in patients with certain neurological disorders, such as Alzheimer’s, multiple sclerosis or amyotrophic lateral sclerosis (ALS).

By Bruce Japsen | Baxter International Inc.’s immune system drug helped preserve “thinking” abilities and reduced brain “shrinkage” in a small group of patients with Alzheimer’s disease that have been studied for 18 months, new research released this afternoon shows.

Washington, Mar 25 : Repetitive anaesthesia with isoflurane (one of the most common anaesthetics by inhalation) increases the risk of developing Alzheimer’s disease (AD) like symptoms in patients with genetic risk factors for the disease, according to a rodent study.

Researchers from Baylor College of Medicine in Houston, Texas studied 597 patients with Alzheimer’s disease in order to evaluate the reliability of the Alzheimer’s progression rate measure in predicting loss of cognition and function.

Pfizer Inc and Medivation, Inc announced results from two phase-3 trials of the investigational drug Dimebon (latrepirdine) in patients with Alzheimer’s disease (AD). In the Connection trial, Dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo.

The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.

Amyloid-beta protein — the primary constituent of the plaques found in the brains of Alzheimer’s disease patients — may be part of the body’s first-line system to defend against infection. In a new study, researchers describe evidence that amyloid-beta protein is an antimicrobial peptide, part of the innate immune system.

Beta amyloid that builds up in the brains of patients with Alzheimer’s disease may go along with beneficial antimicrobial activity, researchers said.

March 3 (Bloomberg) — Beta amyloid that builds up in the brains of patients with Alzheimer’s disease may go along with beneficial antimicrobial activity, researchers said.

LOWELL, Mass., March 2 (UPI) — U.S.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.The study published this month online by Neurobiology of Aging shows that high levels of P- tau231 predict future memory …

The 17th annual event, sponsored by Alzheimer’s Services of the Capital Area, will have a theme of “Diagnosis and Beyond.” WHEN: Wednesday, March 3, 8:30 a.m. to 4 p.m.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.